South Korea · Delayed Price · Currency is KRW Prestige BioPharma Statistics
Total Valuation
KRX:950210 has a market cap or net worth of KRW 116.35 billion. The enterprise value is 205.38 billion.
| Market Cap | 116.35B |
| Enterprise Value | 205.38B |
Important Dates
The last earnings date was Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:950210 has 12.02 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.02M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | -0.69% |
| Owned by Insiders (%) | 30.40% |
| Owned by Institutions (%) | 0.11% |
| Float | 3.59M |
Valuation Ratios
The trailing PE ratio is 42.57.
| PE Ratio | 42.57 |
| Forward PE | n/a |
| PS Ratio | 6.12 |
| PB Ratio | 0.24 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 15.02 |
| EV / Sales | 10.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.08 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.03 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.33 |
| Interest Coverage | -9.58 |
Financial Efficiency
Return on equity (ROE) is -0.86% and return on invested capital (ROIC) is -14.94%.
| Return on Equity (ROE) | -0.86% |
| Return on Assets (ROA) | -6.42% |
| Return on Invested Capital (ROIC) | -14.94% |
| Return on Capital Employed (ROCE) | -13.32% |
| Weighted Average Cost of Capital (WACC) | 7.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 54 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.98 |
Taxes
| Income Tax | -318.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.71% in the last 52 weeks. The beta is 0.76, so KRX:950210's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -22.71% |
| 50-Day Moving Average | 11,159.60 |
| 200-Day Moving Average | 13,107.80 |
| Relative Strength Index (RSI) | 34.64 |
| Average Volume (20 Days) | 114,329 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:950210 had revenue of KRW 19.02 billion and earned 13.68 billion in profits. Earnings per share was 227.41.
| Revenue | 19.02B |
| Gross Profit | -4.89B |
| Operating Income | -73.03B |
| Pretax Income | -4.53B |
| Net Income | 13.68B |
| EBITDA | -48.46B |
| EBIT | -73.03B |
| Earnings Per Share (EPS) | 227.41 |
Balance Sheet
The company has 84.96 billion in cash and 88.62 billion in debt, with a net cash position of -3.66 billion or -304.30 per share.
| Cash & Cash Equivalents | 84.96B |
| Total Debt | 88.62B |
| Net Cash | -3.66B |
| Net Cash Per Share | -304.30 |
| Equity (Book Value) | 482.56B |
| Book Value Per Share | 6,649.00 |
| Working Capital | 3.17B |
Cash Flow
In the last 12 months, operating cash flow was -31.74 billion and capital expenditures -34.94 billion, giving a free cash flow of -66.68 billion.
| Operating Cash Flow | -31.74B |
| Capital Expenditures | -34.94B |
| Depreciation & Amortization | 24.57B |
| Net Borrowing | -67.07B |
| Free Cash Flow | -66.68B |
| FCF Per Share | -5,547.74 |
Margins
Gross margin is -25.70%, with operating and profit margins of -383.88% and 71.89%.
| Gross Margin | -25.70% |
| Operating Margin | -383.88% |
| Pretax Margin | -23.81% |
| Profit Margin | 71.89% |
| EBITDA Margin | -254.73% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KRX:950210 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.25% |
| Shareholder Yield | -0.25% |
| Earnings Yield | 11.75% |
| FCF Yield | -57.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KRX:950210 has an Altman Z-Score of -0.43 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 4 |